Carfilzomib
Small molecule
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Kyprolis (Ono): relapsed or refractory multiple myeloma
- Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01080391 NCT01080391 · Relapsed Multiple Myeloma The 792 participants were randomly assigned to carfilzomib plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, but treatment was open-label rather than blinded. The primary clinical endpoint, progression-free survival, was met, with a median of 26.3 versus 17.6 months and a statistically significant difference (p<0.0001). Registry: NCT01080391 | 3 | Progression-free Survival (PFS) (From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.) 2014-06-16 | Progression-free Survival (PFS) (From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.): Carfilzomib, Lenalidomide, and Dexamethasone (CRd) 26.3 months (95% CI 23.3 to 30.5) vs Lenalidomide and Dexamethasone (Rd) 17.6 months (95% CI 15 to 20.6) | Partial signal | link ↗ |
View 10 more trials
FOCUS NCT01302392 · Multiple Myeloma The trial randomized 315 participants to carfilzomib or best supportive care, but treatment was not blinded. Its primary endpoint was the hard clinical outcome of overall survival, and the comparison did not show a statistically significant benefit for carfilzomib. Registry: NCT01302392 | 3 | Overall Survival (From randomization through the final analysis data cutoff with longest follow-up time of approximately 45 months. Median follow up times were 27.8 months and 29.8 months for Carfilzomib and Best Supportive Care groups, respectively.) 2014-07 | Overall Survival (From randomization through the final analysis data cutoff with longest follow-up time of approximately 45 months. Median follow up times were 27.8 months and 29.8 months for Carfilzomib and Best Supportive Care groups, respectively.): Carfilzomib 10.2 months (95% CI 8.4 to 14.4) vs Best Supportive Care 10 months (95% CI 7.7 to 12) | Partial signal | link ↗ |
IKEMA NCT03275285 · Multiple Myeloma Registry: NCT03275285 | 3 | Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis (From randomization until the primary analysis data cut-off date of 7 Feb 2020 (median duration of follow-up was 20.73 months)); Progression Free Survival as Determined by Independent Response Committee: [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Primary Analysis (From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)); Progression Free Survival as Determined by Independent Response Committee: Final Analysis (From randomization until the final analysis data cut-off date of 14 January 2022 (the median duration of follow-up was 43.96 months)); Progression Free Survival as Determined by Independent Response Committee [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Final Analysis (From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)) 2022-01-14 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
ENDEAVOR NCT01568866 · Multiple Myeloma This was a large randomized active-controlled trial, but it was open-label rather than double-blind. The primary clinical endpoint, independently reviewed progression-free survival, was statistically significantly better with carfilzomib; however, the provided record does not report a power calculation, so the trial receives a moderate evidence grade. Registry: NCT01568866 | 3 | Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively) 2014-11-10 | Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4) | Partial signal | link ↗ |
ARROW NCT02412878 · Multiple Myeloma The trial randomly assigned 478 participants to two active carfilzomib regimens, but treatment was open-label rather than double-blind. Its hard clinical primary endpoint, progression-free survival, favored once-weekly carfilzomib and was statistically significant (p=0.0014); however, the absence of a reported power calculation and the lack of blinding support a moderate evidence grade. Registry: NCT02412878 | 3 | Progression Free Survival (From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for PFS was 12.0 (0, 20) and 12.6 (0, 19) months in each treatment group respectively.) 2017-06-15 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
CANDOR NCT03158688 · Multiple Myeloma Participants were randomized 1:2 to carfilzomib/dexamethasone with or without daratumumab, but the trial was open-label rather than blinded. Among 466 participants, the primary independent-review progression-free survival endpoint was met in favor of adding daratumumab (hazard ratio 0.630, 95% CI 0.464–0.854; p=0.0014), supporting moderate evidence despite the lack of blinding and an unreported power calculation in the provided record. Registry: NCT03158688 | 3 | Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks) 2019-07-14 | Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants | Partial signal | link ↗ |
NCT01998971 NCT01998971 · Multiple Myeloma Registry: NCT01998971 | 1 | Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT) (Up to 30 days after the last dose of study medication); Number of participants affected by dose-limiting toxicities (Up to 30 days after the last dose of study medication) 2019-01-31 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT03412565 NCT03412565 · Multiple Myeloma The carfilzomib cohort was a nonrandomized, open-label, single-arm study of 66 participants receiving daratumumab, carfilzomib, and dexamethasone. Although the clinical primary endpoint, overall response rate, was 84.8%, the uncontrolled design means the result is descriptive rather than a randomized comparison. Registry: NCT03412565 | 2 | D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR) (Up to 2 years 3 months); D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response (Up to 2 years and 3 months) 2020-08-12 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT00531284 NCT00531284 · Non-Small Cell Lung Cancer The study was nonrandomized, unblinded, and had no placebo or active comparator; participants received carfilzomib in dose-escalation and expansion cohorts. Its phase 2 clinical endpoint was reported descriptively rather than through a randomized comparison, with an overall response of 15.4% (65 participants), so the evidence is limited. Registry: NCT00531284 | 1/2 | Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT) (28 days); Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles (4 months) 2014-10 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT00511238 NCT00511238 · Multiple Myeloma The study was open-label, non-randomized, and single-arm, with all participants receiving carfilzomib rather than a placebo or active control. Its clinical response endpoint was reported separately for the two cohorts, but without a controlled comparison, the results provide limited evidence about carfilzomib's effectiveness relative to other treatments. Registry: NCT00511238 | 2 | Best Overall Response Rate (ORR) (A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.) 2010-11 | Best Overall Response Rate (ORR) (A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.): Carfilzomib (A0) 16.7 % of participants w/ PR or better (95% CI 6.97 to 31.36) | Carfilzomib (A1) 23.7 % of participants w/ PR or better (95% CI 18.67 to 29.42) | Weak signal | link ↗ |
NCT00530816 NCT00530816 · Multiple Myeloma This was an open-label, single-arm study without randomization or a comparator; 164 participants received carfilzomib. Its primary endpoint was independently assessed clinical response, but because there was no control arm, there was no formal between-group comparison to establish whether the treatment improved outcomes. Registry: NCT00530816 | 2 | Best Overall Response Rate (ORR) in the Response Evaluable Subset Population (Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.) 2013-01 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (25)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (91)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (48)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (57)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Used as active comparator (9)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
Other Proteasome drugs
Bortezomib, Ixazomib, TQB3602. Compare all 4 Proteasome drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Carfilzomib: this drug | Approved | Small molecule | Proteasome | Partial signal | NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4) | |
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | Partial signal | NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5) NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed | |
| Bortezomib | Approved | Small molecule | Proteasome | Partial signal | NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73 NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001). | |
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | Partial signal | NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023). | |
| Daratumumab | Approved | Monoclonal antibody | CD38 | Partial signal | NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8) NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016). | |
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | Partial signal | NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22) | |
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | Weak signal | Featured results are non-efficacy only in this race | |
| Iberdomide (Zenbexus) | Approved | Small molecule | Cereblon E3 ubiquitin-ligase | not yet graded | No reviewed efficacy summary in this indication | |
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | Reliable signal | NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001) NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8) | |
| Isatuximab | Approved | Monoclonal antibody | CD38 | Partial signal | NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279) | |
| Ixazomib | Approved | Small molecule | Proteasome | Reliable signal | NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47) NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67) | |
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | Reliable signal | NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7) NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1) | |
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Melphalan Hydrochloride (Evomela) | Approved | Small molecule | DNA (guanine N7 position) | Weak signal | NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43 | |
| Motixafortide | Approved | Peptide | CXCR4 | Partial signal | NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel). NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24 | |
| Plerixafor | Approved | Small molecule | CXCR4 | Partial signal | NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009). | |
| Pomalidomide | Approved | Small molecule | Cereblon (CRBN) | Partial signal | NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23% NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9) | |
| Selinexor | Approved | Small molecule | XPO1 (exportin-1) | Partial signal | NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78) | |
| Talquetamab | Approved | Multispecific antibody | GPRC5D x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Teclistamab | Approved | Multispecific antibody | BCMA x CD3 | Partial signal | NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16). NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months | |
| Thalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase | Partial signal | Featured results are non-efficacy only in this race | |
| Zoledronic Acid (Zometa) | Approved | Small molecule | Farnesyl pyrophosphate synthase (FPPS) | not yet graded | No reviewed efficacy summary in this indication | |
| Panobinostat | US approval withdrawn | Small molecule | HDAC | Partial signal | NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014) | |
| Anitocabtagene Autoleucel | Phase 3 | Cell therapy | BCMA | not yet graded | No reviewed efficacy summary in this indication | |
| Arlocabtagene Autoleucel | Phase 3 | Cell therapy | GPRC5D | Weak signal | Featured results are safety only in this race | |
| AZD0120 | Phase 3 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| BCD-264 | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Cevostamab | Phase 3 | Multispecific antibody | FcRH5 (FcRL5) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P44 | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Denosumab (Xgeva) | Phase 3 | Monoclonal antibody | RANKL | Reliable signal | NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014) | |
| Equecabtagene Autoleucel | Phase 3 | Cell therapy | BCMA | not yet graded | No reviewed efficacy summary in this indication | |
| Etentamig | Phase 3 | Multispecific antibody | BCMA x CD3 | Partial signal | NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03). | |
| F182112 | Phase 3 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Felzartamab | Phase 3 | Monoclonal antibody | CD38 | Partial signal | NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035) | |
| Gamgertamig (CM336) | Phase 3 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| HLX15 | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| IBI3003 | Phase 3 | Multispecific antibody | GPRC5D x BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Inobrodib | Phase 3 | Small molecule | CBP/p300 (bromodomain) | not yet graded | No reviewed efficacy summary in this indication | |
| Lumrotatug | Phase 3 | Monoclonal antibody | CD38 | Weak signal | NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days. | |
| Mezigdomide | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | Partial signal | NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09). | |
| Plitidepsin | Phase 3 | Small molecule | eEF1A2 (eukaryotic translation elongation factor 1-alpha 2) | Partial signal | NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2) | |
| QL2109 | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| QLS32015 | Phase 3 | Multispecific antibody | GPRC5D x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| QLS4131 | Phase 3 | Multispecific antibody | GPRC5D x BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ramantamig | Phase 3 | Multispecific antibody | GPRC5D x BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Sanritatug | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 3 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Torutamig | Phase 3 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| TQB2934 | Phase 3 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Velinotamig (GR1803) | Phase 3 | Multispecific antibody | BCMA x CD3 | Weak signal | No reviewed efficacy summary in this indication | |
| Venetoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Burixafor (TG-0054) | Phase 2 | Small molecule | CXCR4 | Weak signal | NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5 NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported. | |
| Cemsidomide | Phase 2 | Small molecule | Cereblon E3 ubiquitin-ligase | not yet graded | No reviewed efficacy summary in this indication | |
| Hrain Anti-BCMA CAR-T | Phase 2 | Cell therapy | BCMA | Weak signal | Featured results are safety only in this race | |
| HRC0202 | Phase 2 | Cell therapy | BCMA | Weak signal | Featured results are safety only in this race | |
| Iopofosine I-131 | Phase 2 | Radiopharmaceutical | phospholipid ether (selective lipid raft | Weak signal | NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen. | |
| LMY-920 | Phase 2 | Cell therapy | BCMA / TACI | not yet graded | No reviewed efficacy summary in this indication | |
| RAPA-201 | Phase 2 | Cell therapy | Rapamycin-resistant autologous T-cell therapy | Weak signal | NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response. | |
| YKST02 | Phase 2 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD4045 | Phase 1/2 | Cell therapy | BCMA | not yet graded | No reviewed efficacy summary in this indication | |
| BCMA CAR-NK (Shenzhen Pregene Biopharma) | Phase 1/2 | Cell therapy | BCMA | Weak signal | No reviewed efficacy summary in this indication | |
| BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech) | Phase 1/2 | Cell therapy | BCMA | not yet graded | No reviewed efficacy summary in this indication | |
| Belantamab | Phase 1/2 | Monoclonal antibody | BCMA | not yet graded | No reviewed efficacy summary in this indication | |
| TQB3602 | Phase 1 | Small molecule | Proteasome | Weak signal | NCT04275583: Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better. |
Large race: only the 63 furthest-along competitors are listed; 104 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(47 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Carfilzomib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.